SCG Cell Therapy and A*STAR’s BTI Collaborate to Advance Multi-Specific Antibody Development

SCG Cell Therapy has signed a collaboration agreement with A*STAR’s BTI to advance the development of antibodies for infectious diseases and cancer treatments.

SCG Cell Therapy, a Singapore-based biotechnology company, announced on March 10, 2022 that it has signed a collaboration agreement with A*STAR’s Bioprocessing Technology Institute (BTI) to advance the development of multi-specific antibodies for infectious diseases and cancer treatments.

The collaboration between the companies will aid in discovering novel therapeutic antibodies and chemistry, manufacturing, and control (CMC) process development to produce more effective, safe, and affordable treatments for patients with infectious diseases and related cancers. There is a specific focus on the hepatitis B virus (HBV) and human papillomavirus (HPV), motivated by the 33 million people in Southeast Asia that have chronic hepatitis B virus, along with the nearly 200,000 deaths in Asia caused by cervical cancer.

Multi-specific antibodies can target multiple antigens on the same or separate cells, which is crucial in the treatment of cancers. These types of antibodies disrupt cancer development or progression by increasing tumor killing selectivity and promoting immune activities.

“The collaboration builds on SCG’s strong international network and capabilities in product development, and BTI’s in-depth expertise in biotherapeutics technology and manufacturing process development,” said Frank Wang Shuli, CEO of SCG Cell Therapy, in a press release. “Together we look forward to accelerating breakthroughs in new antibody-based therapeutics, revolutionizing how we treat chronic infections and cancer.”

Source: SCG Cell Therapy